ATE277594T1 - Vorrichtungen um eine verlängerte medikamententherapie zu erreichen - Google Patents

Vorrichtungen um eine verlängerte medikamententherapie zu erreichen

Info

Publication number
ATE277594T1
ATE277594T1 AT99955212T AT99955212T ATE277594T1 AT E277594 T1 ATE277594 T1 AT E277594T1 AT 99955212 T AT99955212 T AT 99955212T AT 99955212 T AT99955212 T AT 99955212T AT E277594 T1 ATE277594 T1 AT E277594T1
Authority
AT
Austria
Prior art keywords
devices
medication therapy
drug
release
dosage forms
Prior art date
Application number
AT99955212T
Other languages
English (en)
Inventor
Atul D Ayer
Carol A Christopher
Diane R Guinta
Suneel K Gupta
Lawrence G Hamel
Zahedeh Hatamkhany
Andrew C Lam
Samuel R Saks
Padmaja Shivanand
Richard G Weyers
Jeri D Wright
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/253,317 external-priority patent/US6919373B1/en
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE277594T1 publication Critical patent/ATE277594T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/88—Investigating the presence of flaws or contamination
    • G01N21/95—Investigating the presence of flaws or contamination characterised by the material or shape of the object to be examined
    • G01N21/9508—Capsules; Tablets
AT99955212T 1998-06-03 1999-05-27 Vorrichtungen um eine verlängerte medikamententherapie zu erreichen ATE277594T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8778798P 1998-06-03 1998-06-03
US09/253,317 US6919373B1 (en) 1996-11-12 1999-02-19 Methods and devices for providing prolonged drug therapy
PCT/US1999/011920 WO1999062496A1 (en) 1998-06-03 1999-05-27 Methods and devices for providing prolonged drug therapy

Publications (1)

Publication Number Publication Date
ATE277594T1 true ATE277594T1 (de) 2004-10-15

Family

ID=26777397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955212T ATE277594T1 (de) 1998-06-03 1999-05-27 Vorrichtungen um eine verlängerte medikamententherapie zu erreichen

Country Status (16)

Country Link
EP (2) EP1449524A1 (de)
JP (1) JP2002516848A (de)
KR (1) KR20080083074A (de)
CN (1) CN1209098C (de)
AT (1) ATE277594T1 (de)
AU (1) AU4319799A (de)
CA (1) CA2333688A1 (de)
DE (1) DE69920689T2 (de)
DK (1) DK1083879T3 (de)
ES (1) ES2229783T3 (de)
HK (2) HK1035492A1 (de)
IL (1) IL140020A0 (de)
NO (1) NO330235B1 (de)
NZ (1) NZ508567A (de)
PT (1) PT1083879E (de)
WO (1) WO1999062496A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
RU2236847C2 (ru) 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Композиции в виде множества частиц с модифицированным высвобождением
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
WO2001052815A1 (en) * 2000-01-20 2001-07-26 Delsys Pharmaceutical Corporation Multi-step drug dosage forms
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
ATE404179T1 (de) 2001-09-28 2008-08-15 Mcneil Ppc Inc Darreichungsformen mit kern und äusserer hülle
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
DE60316454T2 (de) * 2002-07-29 2008-06-26 Alza Corp., Mountain View Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
RU2005108576A (ru) * 2002-09-28 2005-09-20 МакНЕЙЛ-ППС, ИНК. (US) Полимерная композиция и соднржащие ее лекарственные формы
GR1004330B (el) * 2002-10-14 2003-09-05 Lavipharm A.E. Φαρμακοτεχνικη μορφη για τη χορηγηση οργανικων νιτρικων ενωσεων
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20040197407A1 (en) * 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
ATE544447T1 (de) 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
ES2373042T3 (es) * 2003-10-08 2012-01-30 Mallinckrodt Llc Solución de metilfenidato y procedimientos de administración y producción asociados.
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP1755563B1 (de) * 2004-05-21 2012-01-25 Accu-Break Technologies, Inc. Pharmazeutische tabletten mit zwei oder mehr einheitlichen segmenten
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2009023006A2 (en) * 2006-05-08 2009-02-19 Mcneil-Ppc, Inc. Modified release dosage form
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
CN102238946B (zh) 2008-11-07 2014-11-26 株式会社三养生物制药 用于哌醋甲酯的控制释放的药物组合物
CN102639122A (zh) 2009-12-07 2012-08-15 麦克内尔-Ppc股份有限公司 调释剂型的部分浸渍包衣
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3934622A1 (de) * 2019-03-05 2022-01-12 Amneal Complex Products Research LLC Methylphenidatzusammensetzungen mit verzögerter freisetzung
CN114681422B (zh) * 2020-12-30 2023-09-05 深圳翰宇药业股份有限公司 一种硝苯地平控释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
PT957899E (pt) * 1996-08-16 2003-07-31 Alza Corp Forma de dosagem para proporcionar um medicamento numa dose crescente
DE69735581T2 (de) * 1996-09-30 2007-01-25 Alza Corp., Palo Alto Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung

Also Published As

Publication number Publication date
EP1083879A1 (de) 2001-03-21
CN1209098C (zh) 2005-07-06
KR20080083074A (ko) 2008-09-12
IL140020A0 (en) 2002-02-10
DE69920689D1 (de) 2004-11-04
NO330235B1 (no) 2011-03-07
NO20006007D0 (no) 2000-11-28
DE69920689T2 (de) 2005-02-24
NO20006007L (no) 2001-02-05
AU4319799A (en) 1999-12-20
NZ508567A (en) 2004-02-27
HK1046638B (zh) 2006-02-24
EP1449524A1 (de) 2004-08-25
ES2229783T3 (es) 2005-04-16
CN1352549A (zh) 2002-06-05
EP1083879B1 (de) 2004-09-29
WO1999062496A1 (en) 1999-12-09
HK1046638A1 (en) 2003-01-24
CA2333688A1 (en) 1999-12-09
DK1083879T3 (da) 2005-01-31
JP2002516848A (ja) 2002-06-11
HK1035492A1 (en) 2001-11-30
PT1083879E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
ATE277594T1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
DK1001772T3 (da) Forbedret afgivelse af flere doser af et medikament
CA2386442A1 (en) Apparatus for administering aerosols
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
EP2258362A3 (de) Titrationsdosierschema für kontrolliert freigesetztes Tramadol
NO971206D0 (no) Forlenget-frigjöringsformulering
DK1156790T3 (da) Kombinationer af formoterol og motetason furat
DK0503440T3 (da) Sumatriptanholdige lægemidler
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60207951D1 (de) Pharmazeutische Formulierungen von Thyroidhormonen
DE60225481D1 (de) Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
RU2002122084A (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств
FR2796287B1 (fr) Dispositif d'administration de medicament
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
NO971574D0 (no) Medisinmateanordning for tildeling av medisin via munnen særlig beregnet for mindre barn
HUP0104941A2 (hu) Több gyógyszerformát tartalmazó bliszter
DE60234604D1 (de) Orale dosierungsform enthaltend einen therapeutischen wirkstoff und einen gegenwirdenden wirkstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1083879

Country of ref document: EP